Man Group
AMLX icon

Man Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Man Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,352
Closed -$309K – 2163
2025
Q1 		$309K Sell
87,352
-12,707
-13% -$45.2K ﹤0.01% 1924
2024
Q4 		$378K Sell
100,059
-30,803
-24% -$145K ﹤0.01% 1732
2024
Q3 		$424K Buy
130,862
+14,733
+13% +$33.1K ﹤0.01% 1696
2024
Q2 		$221K Buy
116,129
+55,450
+91% +$107K ﹤0.01% 1862
2024
Q1 		$172K Buy
+60,679
New +$794K ﹤0.01% 2030

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Man Group's AMLX Position: Q2 2025 in Review

Man Group sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 87,352 shares — an estimated $309K sold.

Man Group first reported a position in AMLX in Q1 2024 and held it in 5 quarters. The position peaked at $424K in Q3 2024. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Man Group reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Man Group sold 87,352 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $309K.
  • Man Group first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Man Group's Amylyx Pharmaceuticals position peaked at $424K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Man Group's 13F filing for Q2 2025, filed 14 Aug 2025.